Abstract: A movable forming device (10) to fold a dough piece (P) by moving one end (PS) of the dough piece (P) onto the other end (PT) of the dough piece includes at least one suction tool (23) which holds the one end of the dough piece by suctioning and lifting the one end from its upside, and a supporting tool (33) including a support part (33a) which is movable below the suction tool. The one end of the dough piece is grasped between the suction tool and the supporting part by bringing the suction tool and the supporting part closer to each other.

Abstract: The flow rate control device 10 includes a control valve 11, a restriction part 12 provided downstream of the control valve 11, an upstream pressure sensor 13 for measuring a pressure P1 between the control valve 11 and the restriction part 12, a differential pressure sensor 20 for measuring a differential pressure ?P between the upstream and the downstream of the restriction part 12, and an arithmetic control circuit 16 connected to the control valve 11, the upstream pressure sensor 13, and the differential pressure sensor 20.

Abstract: The head-position sway measuring device (D) includes a touch panel (1a) that gives the instruction to open or close eyes, an acceleration sensor (2a) that measures a displacement of a head position, and a sway recognition unit (1b) that recognizes a head-position sway value based on the displacement of the head position. The acceleration sensor (2a) measures a first measurement value, which is a measurement value obtained in the eye-open state, and then measures a second measurement value, which is a measurement value obtained in the eye-closed state. The sway recognition unit (1b) recognizes the head-position sway value based on the first measurement value and the second measurement value.

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2—OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: The present invention prevents density irregularity from appearing in a print result and to thereby improve image quality by controlling a motor so that the rotational speed of a drive shaft that feeds printing media is constant. The present invention provides a printing media feeding apparatus including a feeding section that includes a motor, a drive transmission mechanism which transmits a driving force of the motor, and a drive shaft to which the driving force is transmitted by the drive transmission mechanism. The drive shaft is rotated to feed the printing medium. A detection section is provided having at least a portion secured to the drive shaft and the detection section determines the rotational speed of the drive shaft and a controller controls the motor based on an input from the detection section so that the rotational speed the of the drive shaft is constant.

Abstract: The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.

Abstract: Disclosed herein is a color adjustment apparatus, including: a color information storage section configured to store color information regarding an arbitrary region designated through a pointer in an editing image region; and a color coordinate explicitly displaying section configured to explicitly display a mark, which specifies color coordinates corresponding to the color information, at a pertaining position on a hue ring or a hue bar chart prepared for color adjustment.

Abstract: The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.

Abstract: A color adjusting apparatus includes a first storage unit for storing information indicating a hue (color phase) range arbitrarily designated in a hue space, a second storage unit for storing an adjustment value for adjusting a degree of color shift in the hue range, and a color conversion unit for performing expansion processing or compression processing on a color component of input image data, the color component being associated with the hue range, in accordance with the degree of color shift determined by the adjustment value.

Abstract: The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.

Abstract: A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.

Abstract: Provided is a continuous production method of a polyamide with stabilized polymerization degree and good quality, particularly an aromatic-containing polyamide.

Abstract: A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.

Abstract: Disclosed herein is a color adjustment apparatus, including: a color information storage section configured to store color information regarding an arbitrary region designated through a pointer in an editing image region; and a color coordinate explicitly displaying section configured to explicitly display a mark, which specifies color coordinates corresponding to the color information, at a pertaining position on a hue ring or a hue bar chart prepared for color adjustment.

Abstract: A color adjusting apparatus includes a first storage unit for storing information indicating a hue (color phase) range arbitrarily designated in a hue space, a second storage unit for storing an adjustment value for adjusting a degree of color shift in the hue range, and a color conversion unit for performing expansion processing or compression processing on a color component of input image data, the color component being associated with the hue range, in accordance with the degree of color shift determined by the adjustment value.

Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.